C5 (UK) will be
holding its 3rd Forum on Biosimilars on December 5, 2013 in London, UK.  C5 faculty will offer presentations on the
following topics:

• Analysing the EMA's monoclonal
antibody guidelines: How to get regulatory approval of your mAb;
• Harmonising your biosimilar development
programme to obtain regulatory approval in Europe and America;
• Updating your chemistry, manufacturing
& control (CMC) strategies in line with evolving global biosimilar
regulations and current market trends;
• Why prescribe?: The medical community's
perception of biosimilars;
• Practical claim drafting and patent
prosecution strategies for biosimilars and innovators;
• Defence strategies for originators: How
to delay competing biosimilars in order to sustain revenue;
• Biosimilars in Brazil; and
• From production to patient: Overcoming
the unique post-approval requirements to market entry facing biosimilars.

A complete brochure
for this conference, including an agenda, list of speakers, detailed descriptions
of conference sessions, and registration form can be downloaded here.

The registration
fee is £1095 (conference alone) or £695 (conference webcast).  Those registering by November 8, 2013 will
receive a £100 discount.  Those
interested in registering for the conference can do so here, by e-mailing
registrations@C5-Online.com, by calling +44 20 7878 6888, or by faxing a
registration form to +44 20 7878 6885.

Patent Docs is a media partner of C5's Biosimilars Forum.